Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $5.9 million.

  • Ultragenyx Pharmaceutical's Interest & Investment Income fell 4536.39% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 2103.97%. This contributed to the annual value of $36.5 million for FY2024, which is 3678.81% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Interest & Investment Income stood at $5.9 million for Q3 2025, which was down 4536.39% from $5.8 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Interest & Investment Income's 5-year high stood at $10.7 million during Q3 2024, with a 5-year trough of $408000.0 in Q3 2021.
  • For the 5-year period, Ultragenyx Pharmaceutical's Interest & Investment Income averaged around $5.0 million, with its median value being $5.9 million (2023).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Interest & Investment Income crashed by 7810.89% in 2021 and then surged by 130863.64% in 2022.
  • Ultragenyx Pharmaceutical's Interest & Investment Income (Quarter) stood at $440000.0 in 2021, then skyrocketed by 1308.64% to $6.2 million in 2022, then soared by 38.0% to $8.6 million in 2023, then grew by 11.66% to $9.5 million in 2024, then plummeted by 38.61% to $5.9 million in 2025.
  • Its Interest & Investment Income stands at $5.9 million for Q3 2025, versus $5.8 million for Q2 2025 and $6.8 million for Q1 2025.